first approval for aniracetam (‘draganon’)
Post on 16-Mar-2017
226 Views
Preview:
TRANSCRIPT
MARKET NEWS
First approval for aniracetam ('Draganon ')
Roche have been granted the first technical approval for their new memory enhancing drug, aniracetam ('Draganon') in Italy. It is indicated for the treatment of cognitive impairment, and is expected to be comarketed by Biomedica Foscama and Menarini in that country.
In one study of 60 patients with cerebral insufficiency, aniracetam produced good or very good improvement in about 61 % of the patients, whereas only 17% improved with placebo therapy. However, in another study of 44 patients with Alzheimer's disease, both placebo and aniracetam recipients showed improvements in performance on several cognitive tests after 3 months.
An NDA for the product has been submitted in Japan by Nippon Roche as 'Draganon' and by Toyama as 'Sarpul'.
1100
ISSN 0156-2703/92/0418-0021/$U)()/O ~ Adis holelhutionullJd
2L
INPHARMA® 18 Apr 1992
top related